Episódios

  • Current State of NETs, Successes, and Future Directions in Latin America
    Sep 9 2025

    This podcast episode discusses the current state of neuroendocrine tumors in Latin America, focusing on the challenges and advancements in diagnosis and treatment. Experts from various countries share insights on the importance of education, registration, and multidisciplinary approaches in managing these tumors. The role of international societies like NANETS in supporting research and education is emphasized, along with the need for increased participation in clinical trials and improved access to treatment options for patients.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    49 minutos
  • The Intersection of Compassion and Burnout in NETs
    Aug 12 2025

    In this conversation, Jason Starr and Jessica Thomas discuss the critical intersection of mental health and oncology. They explore personal experiences with mental health challenges, the prevalence of burnout among healthcare providers, and the importance of resilience and wellness strategies. The discussion also delves into compassion fatigue, the necessity of setting boundaries for self-care, and the value of community support in navigating these challenges. The conversation emphasizes that mental health is a journey and encourages open dialogue about struggles in the healthcare field.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    30 minutos
  • Promising Advances in NEC Research and Treatment
    May 27 2025

    In this podcast, Dr. Garima Gupta meets with Dr. Renuka Iyer and Dr. Aman Chauhan to discuss the latest advancements in the treatment of neuroendocrine carcinomas, focusing on the differences between pulmonary and extra pulmonary types, treatment strategies for extensive stage cases, and the challenges faced in treating platinum refractory patients. They highlight the importance of clinical trials and innovative therapies, including DLL3 targeting and oncolytic virus studies, while emphasizing the need for ongoing research and patient participation in trials.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    38 minutos
  • Understanding the COMPETE Study and Its Implications
    Mar 31 2025

    In this episode of the NET Podcast, Dr. Arshad meets with Dr. Soares, Dr. Shaheen, and Dr. Sonbol at the Tucson Regional Conference to discuss the evolving landscape of neuroendocrine tumors, focusing on recent studies such as the COMPETE study and the implications for treatment sequencing and patient care. They explore the importance of individualized treatment plans, the role of new therapies like cabozantinib, and the real-world challenges faced by patients, including financial toxicity. The conversation highlights the need for ongoing research and collaboration in the field.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    34 minutos
  • Terapias para tumores neuroendocrinos en México
    Feb 25 2025

    ¡Bienvenidos a nuestro primer podcast en español! En este episodio, el Dr. Ismael Domínguez Rosado hablará con la Dra. Cecilia Carreras y la Dra. Mónica Isabel Meneses Medina para revisar la agenda de nuestra Conferencia Regional en la Ciudad de México. Luego, discutirán terapias locales y regionales para tumores endocrinos en México.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    23 minutos
  • 2024 Symposium Abstracts: The Promise of PRRT in Neuroendocrine Tumor Treatment - Recorded November 22nd, 2024
    Jan 14 2025

    In this episode of NETCAST, neuroendocrine experts Dr. Mosalem and Dr. Wahl meet with Taymeyah Al-Toubah discuss the latest advancements in neuroendocrine tumor treatments, focusing on peptide receptor radionuclide therapy (PRRT) with alpha and beta emitters. They delve into the safety and efficacy of new investigational agents, the challenges of hematological toxicity, and the importance of multidisciplinary teams in managing patient care. The conversation highlights the evolving landscape of neuroendocrine tumor therapies and the need for ongoing research and collaboration.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    45 minutos
  • 2024 Symposium Abstracts: New Research Using Biomarkers for Neuroendocrine Tumor Treatment - Recorded November 21st, 2024
    Jan 7 2025

    In this podcast episode, neuroendocrine experts Dr. Liu and Dr. Gujarathi meet with Dr. Phan to discuss the latest advancements in neuroendocrine tumor research, focusing on innovative models for studying G1 and G2 neuroendocrine tumors, the implications of genetic mutations in pancreatic neuroendocrine tumors, and the future of drug screening and treatment protocols. The conversation highlights the importance of developing effective therapies tailored to individual patient profiles and the potential for new biomarkers to guide treatment decisions.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    31 minutos
  • 2024 Symposium Abstracts: Innovative Therapies for Neuroendocrine Tumors - Recorded November 20th, 2024
    Dec 31 2024

    In this episode of NETCAST, leading neuroendocrine experts Dr. Mohammed and Dr. Chauhan meet with Dr. Gangi to discuss their recent studies on innovative therapies for neuroendocrine tumors. Dr. Chauhan presents findings on Peltocetine, a new oral somatostatin receptor agonist, highlighting its efficacy in treating carcinoid syndrome. Dr. Mohammed shares insights on NP101, a combination therapy for metastatic neuroendocrine carcinomas, emphasizing its potential in enhancing treatment outcomes. The conversation explores the future of neuroendocrine cancer treatment, focusing on patient preferences and the importance of ongoing research.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Exibir mais Exibir menos
    18 minutos